Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Seeger

Showing results (211-220 of 266) with videos related to

Pageof 27
Sort By:
Progress in Clinical and Biological Research|January 1, 1994
Comparison of autologous and allogeneic bone marrow transplantation for neuroblastomaK K Matthay, R C Seeger, C P Reynolds, et al.
The Journal of Clinical Investigation|July 1, 1991
High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplificationN Hailat, D R Keim, R F Melhem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group studyM L Schmidt, J N Lukens, R C Seeger, et al.
Medical and Pediatric Oncology|July 24, 2001
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastomaJ M Maris, C Guo, P S White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group studyH J Nickerson, K K Matthay, R C Seeger, et al.
Journal of Neuro-Oncology|February 11, 2018
Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumorsNathan J Robison, Kee Kiat Yeo, Adrian P Berliner, et al.
Cell|July 27, 2010
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcomeMichael Hölzel, Sidong Huang, Jan Koster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer CellsHung C Tran, Zesheng Wan, Michael A Sheard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer GroupK K Matthay, R C Seeger, C P Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2018
Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary NeuroblastomaWesley E Barry, Jeremy R Jackson, Grace E Asuelime, et al.
Pageof 27

Showing results (211-220 of 266) with videos related to

Sort By:
Pageof 27
Progress in Clinical and Biological Research|January 1, 1994
Comparison of autologous and allogeneic bone marrow transplantation for neuroblastomaK K Matthay, R C Seeger, C P Reynolds, et al.
The Journal of Clinical Investigation|July 1, 1991
High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplificationN Hailat, D R Keim, R F Melhem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group studyM L Schmidt, J N Lukens, R C Seeger, et al.
Medical and Pediatric Oncology|July 24, 2001
Allelic deletion at chromosome bands 11q14-23 is common in neuroblastomaJ M Maris, C Guo, P S White, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group studyH J Nickerson, K K Matthay, R C Seeger, et al.
Journal of Neuro-Oncology|February 11, 2018
Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumorsNathan J Robison, Kee Kiat Yeo, Adrian P Berliner, et al.
Cell|July 27, 2010
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcomeMichael Hölzel, Sidong Huang, Jan Koster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer CellsHung C Tran, Zesheng Wan, Michael A Sheard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer GroupK K Matthay, R C Seeger, C P Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2018
Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary NeuroblastomaWesley E Barry, Jeremy R Jackson, Grace E Asuelime, et al.
Pageof 27